Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367483 | 0.83 | PRMT5 (0.41) | NPC1RAB9ASMN1; SMN2L3MBTL1ALK | |
| SCHEMBL17608486 | 0.80 | MAPT (0.38) | NPC1RAB9ASMN1; SMN2ALOX5AP | |
| SCHEMBL1856249 | 0.73 | PRMT5 (0.45) | NPC1RAB9ASMN1; SMN2L3MBTL1ALK | |
| SCHEMBL17608573 | 0.72 | MAPT (0.39) | NPC1RAB9AALK | |
| SCHEMBL14910773 | 0.71 | CYP11B2 (0.42) | NPC1RAB9AL3MBTL1ALK | |
| SCHEMBL4852024 | 0.70 | NOTUM (0.39) | NPC1RAB9ASMN1; SMN2L3MBTL1ALK | |
| SCHEMBL19367485 | 0.69 | ADORA2A (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL2436804 | 0.69 | JAK3 (0.31) | — | |
| SCHEMBL14911037 | 0.69 | HDAC3 (0.52) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1143959 | 0.68 | ALPL (0.54) | NPC1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | VERSEON INTERNATIONAL CORPORATION | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267656-A1 | PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS | SERPINE1, PRSS1, SPINT2 | NPC1 3346/4885RAB9A 2143/4885SMN1; SMN2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.